GE to invest $1 billion in cancer research
September 15, 2011 in CancerUS industrial conglomerate General Electric said on Thursday that it would invest $1 billion in cancer research over the next five years.
GE chief executive Jeff Immelt and several venture capital partners launched the initiative, which will be aimed at improving diagnostic techniques for breast cancer, the company said in a statement.
The investment will go toward research and development into technologies and solutions for cancer detection and treatment, beginning with breast cancer, GE said.
GE and its partners also announced a $100 million "global open innovation challenge" to provide grants to researchers who develop promising early-detection techniques.
The contest will focus on triple negative breast cancer, a particularly aggressive kind of breast cancer which is less responsive to standard treatments than other forms of the disease.
The winners will be announced in the first quarter of 2012 after selection by a jury that includes top cancer scientists as well as representatives of GE and its financial partners, the company said.
"We envision a day when cancer is no longer a deadly disease," Immelt said in the statement.
"When you add our cutting edge cancer detection technologies to the innovative ideas of our new partners, it's a powerful formula for tackling cancer and helping doctors and researchers improve care."
GE's partners in the initiative include top venture-capital firm Kleiner Perkins Caufield & Byers as well as Venrock, Mohr Davidow and MPM Capital.
(c) 2011 AFP
-
Five-year U.K. breast cancer trial starts
Jan 16, 2008 |
not rated yet |
0
-
GE to open advanced tech center in Michigan
Jun 26, 2009 |
not rated yet |
0
-
TechCrunch founder starts venture capital fund
Sep 02, 2011 |
not rated yet |
0
-
New technique to study the genetics of breast cancer
Nov 11, 2008 |
not rated yet |
0
-
Heart disease beats breast cancer as the biggest killer
Jun 19, 2011 |
not rated yet |
0
-
Of mice and mental models: Neuroscientific implications of risk-optimized behavior in the mouse
21 hours ago |
not rated yet |
0
-
Limits to growth: Scientists identify key metastasis-enabling enzyme
May 22, 2012 |
5 / 5 (4) |
0
-
Seeing is as seeing does: Spatially-structured retinal input in early development of cortical maps
Apr 26, 2012 |
5 / 5 (4) |
1
-
Dreamless nights: Brain activity during nonrapid eye movement sleep
Apr 09, 2012 |
4.4 / 5 (12) |
0
-
Take your time: Neurobiology sheds light on the superiority of spaced vs. massed learning
Mar 28, 2012 |
4.5 / 5 (21) |
3
-
A question about drug tolerance
May 23, 2012
-
Poor nutrition leading to overeating?
May 23, 2012
-
Math and dyslexia?
May 21, 2012
-
portable metabolism meter?
May 21, 2012
-
Rare medical conditions on 20/20 tonight
May 18, 2012
-
"Good" Cholesterol in Doubt
May 17, 2012
- More from Physics Forums - Medical Sciences
More news stories
Skp2 activates cancer-promoting, glucose-processing Akt
HER2 and its epidermal growth factor receptor cousins mobilize a specialized protein to activate a major player in cancer development and sugar metabolism, scientists report in the May 25 issue of Cell.
Cancer
15 hours ago |
not rated yet |
0
|
Pancreatectomy OK without downstaging from therapy
(HealthDay) -- Pancreatectomy improves median survival in pancreatic cancer patients even when presurgical neoadjuvant therapy does not lead to radiographic downstaging of tumors, according to a study published ...
Cancer
16 hours ago |
not rated yet |
0
Common therapies for basal cell carcinoma offer similar survival
(HealthDay) -- For patients with superficial basal cell carcinoma (sBCC), treatment with imiquimod or photodynamic therapy (PDT) results in similar long-term tumor-free survival, according to a review published ...
Cancer
17 hours ago |
not rated yet |
0
Cancer may require simpler genetic mutations than previously thought
Chromosomal deletions in DNA often involve just one of two gene copies inherited from either parent. But scientists haven't known how a deletion in one gene from one parent, called a "hemizygous" deletion, can contribute ...
Cancer
19 hours ago |
not rated yet |
0
|
New prostate cancer screening guidelines face a tough sell, study suggests
(Medical Xpress) -- Recent recommendations from the U.S. Preventive Services Task Force (USPSTF) advising elimination of routine prostate-specific antigen (PSA) screening for prostate cancer in healthy men are likely to encounter ...
Cancer
22 hours ago |
not rated yet |
1
Of mice and mental models: Neuroscientific implications of risk-optimized behavior in the mouse
(Medical Xpress) -- Regardless of an organism’s biological complexity, every encephalized animal continuously makes under-informed behavioral choices that can have serious consequences. Despite its ubiquity, ...
Tongue analysis software uses ancient Chinese medicine to warn of disease
For 5,000 years, the Chinese have used a system of medicine based on the flow and balance of positive and negative energies in the body. In this system, the appearance of the tongue is one of the measures used to classify ...
Inherited DNA change explains overactive leukemia gene
A small inherited change in DNA is largely responsible for overactivating a gene linked to poor treatment response in people with acute leukemia.
Early physical therapist treatment associated with reduced risk of healthcare utilization and reduced overall healthcare
A new study published in Spine shows that early treatment by a physical therapist for low back pain (LBP), as compared to delayed treatment, was associated with reduced risk of subsequent healthcare utilization and lower ...
New device allows pacemaker patients to safely undergo MRIs
For many, it's a medical conundrum: The very pacemaker keeping their heart in rhythm prevents them from undergoing an MRI to diagnose other ailments, because interaction between the two devices could prove deadly.
First study to suggest that the immune system may protect against Alzheimer's changes in humans
Recent work in mice suggested that the immune system is involved in removing beta-amyloid, the main Alzheimer's-causing substance in the brain. Researchers have now shown for the first time that this may apply in humans.